Dr Serge Gauthier - Chairman

Dr Gauthier is credited with setting up the first multicentre Canadian study of tacrine as a treatment for Alzheimer's disease, as well as with creating the Consortium of Canadian Centres for Clinical Cognitive Research (C5R). Director of the Alzheimer’s Disease Research Unit, McGill Centre for Studies in Ageing, Quebec, Canada, he is famous for his outstanding contributions to the development of new diagnostic and therapeutic approaches to Alzheimer's disease and other disorders of dementia.

Dr Lon. S. Schneider

Professor of psychiatry and the behavioural sciences and neurology, Keck School of Medicine of USC, California, Dr Schneider directs the USC’s State of California Alzheimer’s Disease Research and Clinical Center and the clinical core of the USC NIA Alzheimer’s Disease Research Center. He serves as editor-in-chief of Alzheimer’s and Dementia: Translational Research & Clinical Interventions and has authored over 400 papers and chapters.

Prof. Gordon Wilcock

Professor Wilcock (Emeritus, Oxford) was the founder chairman of the Alzheimer's Society UK (formerly Alzheimer's Disease Society), has worked with the Medical Research Council, Royal College of Physicians, British Geriatric Society and the Department of Health and also served as a member of national and international consensus working parties. He has written and co-edited a number of books and chapters, primarily on Alzheimer's disease and dementia, but also in the wider context of care of the elderly. In 2015, he was awarded the CTAD Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research and the Silver Medal from the International Association for Gerontology and Geriatrics.

Prof. Howard Feldman

A prolific physician-scientist credited with several key contributions in geriatric cognitive disorders, Alzheimer’s disease and other dementias including frontotemporal dementia, Professor Feldman is Professor of Neurology in the Faculty of Medicine, University of British Columbia, Canada. He has long been active in translating basic research into treatments that benefit patients and a lead principal investigator on numerous clinical trials in this field, including the use of cholinesterase inhibitors for Alzheimer’s disease and mild cognitive impairment, as well as other experimental approaches.

Prof. Giovanni Frisoni

Imaging Expert and Professor of Clinical Neuroscience and Head of Memory Clinic, University Hospital of Geneva and University of Geneva, Switzerland, for over 20 years, Professor Frisoni’s scientific interests have encompassed the clinical neuroimaging of Alzheimer’s disease and other cognitive disorders. The imaging section editor of Neurobiology of Aging and an editorial board member for The Lancet Neurology, he has served as the principal or co-principal investigator or scientific coordinator for several research studies and has secured extensive funding to advance the study and understanding of cognitive disorders.